Abstract:Objective:To explore the improvement of bone mineral density by deferoxamine (DFO) effects on blood vessels in bone.Methods:Thirty C57BL/6J wild-type mice were used for this experiment (Model Animal Research Center of Nanjing University). Eight-week-old female mice were randomly divided into three groups including a sham operation (Sham), bilateral ovariectomy (OVX) and intraperitoneal injection DFO (OVX+ DFO). There are ten mice in every group. In the sham group, the ovaries were only exposed but left intact. The bilateral ovaries were exposed and complete excision in the OVX group. In the OVX+ DFO group, the mice were treated with DFO intervention four weeks by intraperitoneal injection every other day. In the other two groups, the mice were administrated with normal saline equivalent. After 4 weeks, these mice were killed for experiment and the femurs were collected for Micro-CT scanning in order to observe the changes of bone mineral density (BMD) and trabecular indexes, including bone volume fraction (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp) and connectivity density (Conn. Dn). The fresh tibia of each mouse was fixed, decalcified, dehydrated and embedded for immunostaining in order to observe the type H vessels in the metaphysis of the bone. All experimental data were collected for statistical analysis by single factor Analysis of Variance (ANOVA).Results:Mouse femora from three groups were dissected at 4-week time points, and the attached soft tissue was completely removed for Micro-CT scanning. The value of BMD is (0.18±0.01) g/cm 3 in Sham group, (0.12±0.00) g/cm 3 in OVX group and (0.16±0.01) g/cm 3 in OVX+ DFO, which indicated the BMD in OVX + DFO group significantly improved by comparing with OVX group. The results showed significant difference among the groups ( F=20.790, P<0.01). The microarchitecture in trabecular bone had changed. The value of BV/TV is (11.47±0.79)% in OVX group, (26.05±2.05)% in Sham group and (18.44±3.26)% in OVX+ DFO group, which indicated the BV/TV in OVX significantly decreased and some improvement in DFO interventions. The results showed significant difference among the groups ( F=31.000, P<0.01). The number of Tb.N is (1.63±0.15)/mm in OVX group, (2.81±0.13)/mm in Sham group, and (2.36±0.43)/mm in OVX+ DFO group, which indicated the Tb.N in OVX+ DFO group increased. The results showed significant difference among the groups ( F=14.290, P<0.01). The value of Tb.Th in OVX group is (0.05±0.01) mm, (0.07±0.00) mm in Sham group and (0.06±0.00) mm in OVX+ DFO group, which indicated the Tb.Th in OVX+ DFO group significantly thickened. The results showed significant difference among the groups ( F=20.060, P<0.01). Tb.Sp in OVX group is (0.29±0.03) mm, (0.19±0.01) mm in Sham group and (0.24±0.04) mm in OVX+ DFO group, which indicated the Tb.Sp in OVX significantly increased and partially improved via DFO interventions. The results showed significant difference among the groups ( F=9.450, P<0.05). Conn. Dn in Sham group is (202.67±37.75)/mm 3, (97.85±8.62)/mm 3 in OVX group and (115.79±15.90)/mm 3 in OVX+ DFO group. The results showed significant difference between the groups ( F=16.140, P<0.01). The tibialspecimes were collected for immunostaining in order to observe the changes of type H vessel in the metathysis of the bone among the three groups. The area of type H vessels in bone was calculated. The percentage of HV/TV in Sham group was (26.28±1.23)%, (8.72±0.85)% in OVX group and (17.25±2.14)% in OVX+ DFO group. Dramatically increased type H vessels in the metaphysis of OVX+ DFO group were observed compared with that of OVX group. The results showed significant difference among the groups ( F=160.000, P<0.01). Conclusion:The ovariectomized mice model study, type H vessels in bone involved the occurrence of osteoporosis. DFO maybe improve the bone mineral density by enhancing the type H vessels formation.

The effect of deferoxamine on bone mineral density in patients with transfusion-associated iron overload

Effect of deferoxamine administration on the treatment of iron accumulation-induced osteopenia in male mice

Effects of deferoxamine and iron overload on bone mass of male mice

The Effect and Relative Mechanism of Deferoxamine on Bone Mass in Ovariectomized Mice Companied with Iron Accumulation

Effect of Deferoxamine on Osteoblast Differentiation under Iron Overload Environment

Effects of deferasirox on bone mass and construction in ovariectomy mice with iron accumulation

Clinical Investigation of Dependent-Transfusion Iron Overload in Patients with Myelodysplastic Syndromes and Primary Myelofibrosis

Deferasirox and Deferoxamine in Treatment for Iron Overload in Transfusion Dependent Thalassemia

High ferritin is associated with liver and bone marrow iron accumulation: Effects of 1-year deferoxamine treatment in hemodialysis-associated iron overload

Effect of deferoxamine on the bone-related gene expression in human osteoblasts in vitro

Therapeutic Effect of Deferoxamine on Iron Overload-Induced Inhibition of Osteogenesis in a Zebrafish Model

The Effect of Intermittent Deferoxamine Therapy on Relieving Iron Overload in Children with Β Thalassemia

SF-deferoxamine, a Bone-Seeking Angiogenic Drug, Prevents Bone Loss in Estrogen-Deficient Mice

Bone mineral density in patients with transfusion-associated iron accumulation

Experimental research of deferoxamineon the improvement of bone mineral density via enhancing angiogenesis in bone

Efficacy of deferasirox in iron overload patients secondary to myelodysplastic syndrome

Effect of desferioxamine on the expression of multidrug resistance gene 1 and nuclear factor κB in K562 cells

Effect of iron overload on endothelial cell calcification and its mechanism

Efficacy and Safety of Deferasirox in Aplastic Anemia Patients with Iron Overload:A Single Arm, Multi-Center, Prospective Study in China

Synergistic protection of bone vasculature and bone mass by desferrioxamine in osteoporotic mice.

Clinical effect of intravenous iron dextran on peritoneal dialysis patients with renal anemia